Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07006506 · ClinicalTrials.gov registry record · Phase 2
A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
A Phase 2 study of Hematologic Malignancy and Graft-Versus-Host Disease, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
- 7
- Study locations
NCT07006506 is a Phase 2 study of Hematologic Malignancy and Graft-Versus-Host Disease that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 46 participants, below the 228-participant average among 48 other Hematologic Malignancy trials with a reported enrollment target (80% lower). The trial reports 7 study locations across 2 states.
The verdict
NCT07006506, a Phase 2 study of Hematologic Malignancy and Graft-Versus-Host Disease, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to find out whether adding belumosudil to a usual approach for reducing the risk of graft-versus-host disease (GVHD) may be an effective GVHD prevention approach for people with blood cancer who have a stem cell transplant. The investigators will also look at the safety of the study approach.
Conditions Studied
Interventions
- DRUG Belumosudil
Study Locations (7)
New York
- Memorial Sloan Kettering Suffolk-Commack (Limited protocol activity) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activites) - Rockville Centre
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2025-05-21 |
| Est. Completion | 2029-05-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07006506
The ClinicalTrials.gov registry entry for NCT07006506 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 228-participant average among 48 other Hematologic Malignancy trials with a reported enrollment target (80% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Hematologic Malignancy appearing as the primary indexed condition, and to 1 intervention - of which Belumosudil is the first listed.
NCT07006506 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT07006506 about?
NCT07006506 is a clinical study titled "A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant". The purpose of this study is to find out whether adding belumosudil to a usual approach for reducing the risk of graft-versus-host disease (GVHD) may be an effective GVHD prevention approach for people with blood cancer who have a stem cell transplant. The investigators will also look at the safety ...
What is the current status of trial NCT07006506?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2025-05-21. Estimated completion is 2029-05-21.
What conditions does trial NCT07006506 study?
This clinical trial studies the following conditions: Hematologic Malignancy, Graft-Versus-Host Disease, Graft Vs Host Disease.
What interventions are being tested in trial NCT07006506?
The interventions under investigation include: Belumosudil (DRUG).
Who is sponsoring clinical trial NCT07006506?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07006506 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Malignancy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
RECRUITING · Phase 2
-
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
RECRUITING · Phase 2
-
Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies
ACTIVE NOT RECRUITING · Phase 2
-
Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation
ACTIVE NOT RECRUITING · Phase 2
-
PROACTIVE: Preventing Acute/Chronic GVHD With TocIlizumab Combined With GVHD Prophylaxis Post allogEneic Transplant
COMPLETED · Phase 2
-
FDG-PET as an Imaging Modality to Diagnose and Risk Stratify Subclinical, Imaging Negative Ici-Myocarditis
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.